124
Views
0
CrossRef citations to date
0
Altmetric
Original Research

The Usefulness of FEF25–75 in Predicting Airway Hyperresponsiveness to Mannitol

ORCID Icon, ORCID Icon, , ORCID Icon, ORCID Icon, , ORCID Icon, ORCID Icon, ORCID Icon, , ORCID Icon & show all
Pages 1267-1275 | Published online: 28 Oct 2021

References

  • Sposato B, Scalese M, Migliorini MG, Di Tomassi M, Scala R. Small airway impairment and bronchial hyperresponsiveness in asthma onset. Allergy Asthma Immunol Res. 2014;6(3):242–251. doi:10.4168/aair.2014.6.3.242
  • Cho EY, Oh KJ, Rhee CK, et al. Comparison of clinical characteristics and management of asthma by types of health care in South Korea. J Thorac Dis. 2018;10(6):3269–3276. doi:10.21037/jtd.2018.05.95
  • Choi JY, Yoon HK, Lee JH, et al. Current status of asthma care in South Korea: nationwide the health insurance review and assessment service database. J Thorac Dis. 2017;9(9):3208–3214. doi:10.21037/jtd.2017.08.109
  • 2020 GINA Report. Global Strategy for Asthma Management and Prevention; 2020.
  • Lipworth BJ, Clark DJ. Effects of airway calibre on lung delivery of nebulised salbutamol. Thorax. 1997;52(12):1036–1039. doi:10.1136/thx.52.12.1036
  • Malerba M, Radaeli A, Olivini A, et al. Association of FEF25–75% impairment with bronchial hyperresponsiveness and airway inflammation in subjects with asthma-like symptoms. Respiration. 2016;91(3):206–214. doi:10.1159/000443797
  • Munoz-Lopez F, Rios-Alcolea M. The interest of FEF(25s–75) in evaluating bronchial hyperresponsiveness with the methacholine test. Allergol Immunopathol. 2012;40(6):352–356. doi:10.1016/j.aller.2011.07.003
  • Ciprandi G, Cirillo I. Forced expiratory flow between 25% and 75% of vital capacity may be a marker of bronchial impairment in allergic rhinitis. J Allergy Clin Immunol. 2011;127(2):549; discussion 550–1. doi:10.1016/j.jaci.2010.10.053
  • Alberts WM, Ferris MC, Brooks SM, Goldman AL. The FEF25–75% and the clinical diagnosis of asthma. Ann Allergy. 1994;73(3):221–225.
  • Anderson SD. Indirect challenge tests: airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest. 2010;138(2Suppl):25S–30S. doi:10.1378/chest.10-0116
  • Lee J, Song JU. Diagnostic comparison of methacholine and mannitol bronchial challenge tests for identifying bronchial hyperresponsiveness in asthma: a systematic review and meta-analysis. J Asthma. 2020;1–9. doi:10.1080/02770903.2020.1739704
  • Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179–191. doi:10.7326/0003-4819-155-3-201108020-00008
  • Anderson SD, Brannan J, Spring J, et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med. 1997;156(3 Pt 1):758–765. doi:10.1164/ajrccm.156.3.9701113
  • Schisterman EF, Faraggi D, Reiser B, Hu J. Youden index and the optimal threshold for markers with mass at zero. Stat Med. 2008;27(2):297–315. doi:10.1002/sim.2993
  • Grootendorst DC, Rabe KF. Mechanisms of bronchial hyperreactivity in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1(2):77–87. doi:10.1513/pats.2306025
  • Kim MH, Song WJ, Kim TW, et al. Diagnostic properties of the methacholine and mannitol bronchial challenge tests: a comparison study. Respirology. 2014;19(6):852–856. doi:10.1111/resp.12334
  • Lim SY, Jo YJ, Chun EM. The correlation between the bronchial hyperresponsiveness to methacholine and asthma like symptoms by GINA questionnaires for the diagnosis of asthma. Validation studies. BMC Pulm Med. 2014;14(161):161. doi:10.1186/1471-2466-14-161
  • Quanjer PH, Weiner DJ, Pretto JJ, Brazzale DJ, Boros PW. Measurement of FEF25–75% and FEF75% does not contribute to clinical decision making. Eur Respir J. 2014;43(4):1051–1058. doi:10.1183/09031936.00128113
  • Strunk RC, Szefler SJ, Phillips BR, et al. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol. 2003;112(5):883–892. doi:10.1016/j.jaci.2003.08.014
  • Lusuardi M, De Benedetto F, Paggiaro P, et al. A randomized controlled trial on office spirometry in asthma and COPD in standard general practice: data from spirometry in Asthma and COPD: a comparative evaluation Italian study. Chest. 2006;129(4):844–852. doi:10.1378/chest.129.4.844
  • Rao DR, Gaffin JM, Baxi SN, Sheehan WJ, Hoffman EB, Phipatanakul W. The utility of forced expiratory flow between 25% and 75% of vital capacity in predicting childhood asthma morbidity and severity. J Asthma. 2012;49(6):586–592. doi:10.3109/02770903.2012.690481
  • Raji H, Haddadzadeh Shoushtari M, Idani E, et al. Forced expiratory flow at 25–75% as a marker for airway hyper responsiveness in adult patients with asthma-like symptoms. Tanaffos. 2018;17(2):90–95.